Seongseok Yun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1121620/publications.pdf

Version: 2024-02-01

623574 552653 28 718 14 26 citations g-index h-index papers 32 32 32 1611 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Late Onset Ipilimumab-Induced Pericarditis and Pericardial Effusion: A Rare but Life Threatening Complication. Case Reports in Oncological Medicine, 2015, 2015, 1-5.	0.2	90
2	Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and metaâ€analysis of antiâ€CTLAâ€4 and antiâ€PDâ€1 agents trials. Cancer Medicine, 2016, 5, 1481-1491.	1.3	86
3	Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled Trials. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 31-37.e13.	0.2	77
4	Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials. Clinical Epigenetics, 2016, 8, 68.	1.8	62
5	Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review. Critical Reviews in Oncology/Hematology, 2017, 109, 42-50.	2.0	59
6	4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells. Blood, 2016, 127, 2711-2722.	0.6	49
7	Cardioprotective role of \hat{l}^2 -blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis. Postgraduate Medical Journal, 2015, 91, 627-633.	0.9	42
8	Waldenström Macroglobulinemia: Review of Pathogenesis and Management. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 252-262.	0.2	38
9	Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, e85-e94.	0.2	33
10	Update on iron metabolism and molecular perspective of common genetic and acquired disorder, hemochromatosis. Critical Reviews in Oncology/Hematology, 2015, 95, 12-25.	2.0	32
11	Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML). Leukemia, 2021, 35, 1145-1155.	3.3	27
12	TFEB Links MYC Signaling to Epigenetic Control of Myeloid Differentiation and Acute Myeloid Leukemia. Blood Cancer Discovery, 2021, 2, 162-185.	2.6	22
13	Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC). Leukemia Research, 2019, 84, 106194.	0.4	18
14	The great masquerader of malignancy: chronic intestinal pseudo-obstruction. Biomarker Research, 2014, 2, 23.	2.8	17
15	Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Children and Young Adults with Relapsed Ewing's Sarcoma: A Systematic Review. Sarcoma, 2018, 2018, 1-12.	0.7	15
16	Disrupting the MYC-TFEB Circuit Impairs Amino Acid Homeostasis and Provokes Metabolic Anergy. Cancer Research, 2022, 82, 1234-1250.	0.4	8
17	A Rare Presentation ofIn SituMantle Cell Lymphoma and Follicular Lymphoma: A Case Report and Review of the Literature. Case Reports in Hematology, 2014, 2014, 1-7.	0.3	7
18	Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag. Case Reports in Hematology, 2015, 2015, 1-3.	0.3	7

#	Article	IF	CITATIONS
19	Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia. Immunotherapy, 2016, 8, 847-852.	1.0	7
20	Role of Maintenance Therapy after High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas: A Systematic Review. Biology of Blood and Marrow Transplantation, 2016, 22, 1182-1196.	2.0	6
21	MYC Overexpression is Associated with an Early Disease Progression from MDS to AML. Leukemia Research, 2021, 111, 106733.	0.4	6
22	Allogeneic Transplant in ELANE and MEFV Mutation Positive Severe Cyclic Neutropenia: Review of Prognostic Factors for Secondary Severe Events. Case Reports in Hematology, 2017, 2017, 1-7.	0.3	4
23	Nephrotic Syndrome Secondary to Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits of Lambda Light Chain. Case Reports in Nephrology, 2014, 2014, 1-6.	0.2	2
24	C-MYC Augments the Proliferation and Survival of Hematopoietic Stem Cells and Multipotent Progenitors to Drive Myeloproliferative Neoplasms. Blood, 2021, 138, 28-28.	0.6	2
25	Rare transformation to double hit lymphoma in Waldenstrom's macroglobulinemia. Immunotherapy, 2017, 9, 709-714.	1.0	1
26	Gilteritinib Combined with Azacitidine as Salvage Therapy for B/Myeloid Mixed Phenotype Acute Leukemia. Cureus, 2022, 14, e23618.	0.2	1
27	Waxing and Waning Pruritic Cutaneous Lesions Refractory to Antibiotic Treatment. JAMA Oncology, 2016, 2, 1501.	3.4	O
28	Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemia. JAMA Oncology, 2016, 2, 828.	3.4	0